Skip to main content
Year archive

Purple Biotech Ltd. — 2020 filings

All 164 regulatory filings released by Purple Biotech Ltd. (PPBT) in 2020, sourced directly from the official regulator.

164 Filings
2020 Period
2020 filings (164)
Filing Released Lang
Immediate Report about change of identifying details
Regulatory Filings
2020-12-28 English
CHANGES IN COMPANY'S AND SECURITIES NAMES EFFECTIVE OF December 22, 2020
Regulatory Filings
2020-12-20 Hebrew (modern)
Immediate Report on Change in Association Documents
Regulatory Filings
2020-12-10 English
Immediate Report on Change in Association Documents
Report Publication Announcement
2020-12-10 English
Kitov Announces Name Change to Purple Biotech Ltd
Regulatory Filings
2020-12-10 Hebrew (modern)
Kitov Announces Name Change to Purple Biotech Ltd
Regulatory Filings
2020-12-10 English
results of the Annual General Meeting of Shareholders of the Company held on December 3, 2020
AGM Information
2020-12-06 English
results of the Annual General Meeting of Shareholders of the Company held on December 3, 2020
Regulatory Filings
2020-12-06 English
KITOV PHARMA COMPANY PRESENTATION NOVEMBER 2020
Investor Presentation
2020-11-12 English
KITOV PHARMA COMPANY PRESENTATION NOVEMBER 2020
Regulatory Filings
2020-11-12 English
Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb
Regulatory Filings
2020-11-09 English
Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb
Regulatory Filings
2020-11-09 English
6k: Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
Regulatory Filings
2020-10-27 English
6k: Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
Regulatory Filings
2020-10-27 English
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
Regulatory Filings
2020-10-27 English
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
Report Publication Announcement
2020-10-27 English
Annual General Meeting of Shareholders to be held on December 3, 2020
AGM Information
2020-10-24 English
Annual General Meeting of Shareholders to be held on December 3, 2020
AGM Information
2020-10-24 English
Annual General Meeting of Shareholders to be held on December 3, 2020
AGM Information
2020-10-24 English
Annual General Meeting of Shareholders to be held on December 3, 2020
AGM Information
2020-10-24 English
Annual General Meeting of Shareholders to be held on December 3, 2020
Regulatory Filings
2020-10-24 English
PR: New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference
Regulatory Filings
2020-10-18 English
PR: New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference
Regulatory Filings
2020-10-18 English
6K:Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patient
Regulatory Filings
2020-09-08 English
6K:Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patient
Regulatory Filings
2020-09-08 English
Received a notification letter from Nasdaq stating that the Company has regained compliance with its minimum bid price
Regulatory Filings
2020-09-08 English
Received a notification letter from Nasdaq stating that the Company has regained compliance with its minimum bid price
Regulatory Filings
2020-09-08 English
Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219
Regulatory Filings
2020-09-08 English
Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219
Regulatory Filings
2020-09-08 English
Receives Notice of Intention to Grant Two Patents in China Covering Company’s Lead Oncology Assets, CM24 and NT219
Regulatory Filings
2020-09-06 English
Receives Notice of Intention to Grant Two Patents in China Covering Company’s Lead Oncology Assets, CM24 and NT219
Regulatory Filings
2020-09-06 English
Amended and Restated Articles of Association; Amended and Restated Memorandum of Association
Regulatory Filings
2020-08-17 English
Amended and Restated Articles of Association; Amended and Restated Memorandum of Association
Report Publication Announcement
2020-08-17 English
The Company will change the ratio of its American Depositary Shares to ordinary shares to 1:10, The ratio change will be effective at the beginning of trading on August 21, 2020
Regulatory Filings
2020-08-13 English
The Company will change the ratio of its American Depositary Shares to ordinary shares to 1:10, The ratio change will be effective at the beginning of trading on August 21, 2020
Regulatory Filings
2020-08-13 English
Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results
Interim / Quarterly Report H1 2020
2020-08-11 English
Kitov Pharma Provides Corporate Update and Reports First Half 2020 Financial Results
Report Publication Announcement H1 2020
2020-08-11 English
Provides Corporate Update and Reports First Half 2020 Financial
Earnings Release H1 2020
2020-08-11 English
Provides Corporate Update and Reports First Half 2020 Financial
Report Publication Announcement
2020-08-11 English
Results of the extraordinary general meeting of shareholders of the Company
Declaration of Voting Results & Voting Rights Announcements
2020-08-09 English
Results of the extraordinary general meeting of shareholders of the Company
AGM Information
2020-08-09 English
FORM D-Notice of Exempt Offering of Securities
Regulatory Filings
2020-07-15 English
FORM D-Notice of Exempt Offering of Securities
Report Publication Announcement
2020-07-15 English
Post-Effective Amendment No. 1 to FORM F-1 on FORM F-3
Regulatory Filings
2020-07-11 English
Post-Effective Amendment No. 1 to FORM F-1 on FORM F-3
Regulatory Filings
2020-07-11 English
Form F-3- REGISTRATION STATEMENT
Capital/Financing Update
2020-07-11 English
Form F-3- REGISTRATION STATEMENT
Regulatory Filings
2020-07-11 English
PR: Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
Regulatory Filings
2020-07-09 English
PR: Announces Initiation of Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
Regulatory Filings
2020-07-09 English
Receives Notice of Intention to Grant a European Patent Covering CM24
Regulatory Filings
2020-07-08 English
Receives Notice of Intention to Grant a European Patent Covering CM24
Regulatory Filings
2020-07-08 English
13G-Statement of acquisition of beneficial ownership by individuals-Armistice Capital, LLC
Major Shareholding Notification
2020-07-07 English
13G-Statement of acquisition of beneficial ownership by individuals-Armistice Capital, LLC
Director's Dealing
2020-07-07 English
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
Proxy Solicitation & Information Statement
2020-07-02 English
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
Proxy Solicitation & Information Statement
2020-07-02 English
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
AGM Information
2020-07-02 English
Extraordinary General Meeting of Shareholders
Proxy Solicitation & Information Statement
2020-07-02 English
Extraordinary General Meeting of Shareholders
AGM Information
2020-07-02 English
Issues CEO Shareholder Letter Providing Business Update
Regulatory Filings
2020-07-02 English
Issues CEO Shareholder Letter Providing Business Update
Report Publication Announcement
2020-07-02 English
Notice of Extraordinary General Meeting of Shareholders will be held on August 6, 2020
AGM Information
2020-07-01 English
Notice of Extraordinary General Meeting of Shareholders will be held on August 6, 2020
AGM Information
2020-07-01 English
Amends the initial submission of the Form 6-K to replace Form of Placement Agent Warrant included as Exhibit 4.2 in the initial submission to reflect the correct exercise price of $1.125 per ADS, inst
Regulatory Filings
2020-06-29 English
Amends the initial submission of the Form 6-K to replace Form of Placement Agent Warrant included as Exhibit 4.2 in the initial submission to reflect the correct exercise price of $1.125 per ADS, inst
Regulatory Filings
2020-06-29 English
Kitov Closes $35 Million Registered Direct Offering
Regulatory Filings
2020-06-26 English
Kitov Closes $35 Million Registered Direct Offering
Regulatory Filings
2020-06-26 English
FORM 6-K-exhibits attached
Regulatory Filings
2020-06-25 English
FORM 6-K-exhibits attached
Regulatory Filings
2020-06-25 English
PROSPECTUS SUPPLEMENT to Prospectus dated December 13, 2019
Capital/Financing Update
2020-06-25 English
PROSPECTUS SUPPLEMENT to Prospectus dated December 13, 2019
Capital/Financing Update
2020-06-25 English
Kitov Announces $35.0 Million Registered Direct Offering
Regulatory Filings
2020-06-23 English
Kitov Announces $35.0 Million Registered Direct Offering
Regulatory Filings
2020-06-23 English
Kitov Announces FDA Acceptance of IND Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients
Regulatory Filings
2020-05-23 English
Kitov Announces FDA Acceptance of IND Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients
Regulatory Filings
2020-05-23 English
6K:Kitov Announces U.S. Commercial Launch of Consensi™
Regulatory Filings
2020-05-20 English
6K:Kitov Announces U.S. Commercial Launch of Consensi™
Regulatory Filings
2020-05-20 English
PR: Kitov Announces U.S. Commercial Launch of Consensi™
Regulatory Filings
2020-05-20 English
PR: Kitov Announces U.S. Commercial Launch of Consensi™
Report Publication Announcement
2020-05-20 English
FORM 6-K-Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II
Regulatory Filings
2020-05-19 English
FORM 6-K-Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II
Regulatory Filings
2020-05-19 English
Press Release: Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting
Regulatory Filings
2020-05-19 English
Press Release: Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting
Report Publication Announcement
2020-05-19 English
FORM S-8-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Capital/Financing Update
2020-05-18 English
FORM S-8-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
Report Publication Announcement
2020-05-18 English
FORM D-Notice of Exempt Offering of Securities
Capital/Financing Update
2020-05-16 English
FORM D-Notice of Exempt Offering of Securities
Capital/Financing Update
2020-05-16 English
SCHEDULE 13G
Major Shareholding Notification
2020-05-16 English
SCHEDULE 13G
Major Shareholding Notification
2020-05-16 English
Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific Program
Regulatory Filings
2020-05-14 English
Kitov to Present Phase 1 Data on CM-24 in Patients with Advanced Cancer at American Society of Clinical Oncology 2020 Virtual Scientific Program
Regulatory Filings
2020-05-14 English
F-3-Approximate date of commencement of proposed sale to the public
Capital/Financing Update
2020-05-13 English
F-3-Approximate date of commencement of proposed sale to the public
Regulatory Filings
2020-05-13 English
K-6 -Kitov Closes $10 Million Registered Direct Offering
Regulatory Filings
2020-05-09 English
K-6 -Kitov Closes $10 Million Registered Direct Offering
Regulatory Filings
2020-05-09 English
FORM 6-K Report of Foreign Private
Regulatory Filings
2020-05-09 English
FORM 6-K Report of Foreign Private
Regulatory Filings
2020-05-09 English
PROSPECTUS SUPPLEMENT 6.5.20
Capital/Financing Update
2020-05-09 English
PROSPECTUS SUPPLEMENT 6.5.20
Capital/Financing Update
2020-05-09 English
6k: Kitov Announces $10 million Registered Direct Offering
Regulatory Filings
2020-05-06 English
6k: Kitov Announces $10 million Registered Direct Offering
Regulatory Filings
2020-05-06 English
Schedule 13G filing with the SEC by Sabby Volatility Warrant Master Fund, Ltd. / Sabby Management, LLC / Hal Mintz concerning their holdings in the Company
Major Shareholding Notification
2020-05-06 English
Schedule 13G filing with the SEC by Sabby Volatility Warrant Master Fund, Ltd. / Sabby Management, LLC / Hal Mintz concerning their holdings in the Company
Major Shareholding Notification
2020-05-06 English
Kitov Announces $10 million Registered Direct Offering
Capital/Financing Update
2020-05-06 English
Kitov Announces $10 million Registered Direct Offering
Capital/Financing Update
2020-05-06 English
FORM D-Notice of Exempt Offering of Securities
Capital/Financing Update
2020-05-04 English
FORM D-Notice of Exempt Offering of Securities
Capital/Financing Update
2020-05-04 English
Company Presentation - May 2020
Investor Presentation
2020-05-04 English
Company Presentation - May 2020
Regulatory Filings
2020-05-04 English
6K: Material Agreement and Press Release: Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants,Extension of Second Nasdaq Compliance Period to Comply with Bid Price Rule
Regulatory Filings
2020-04-20 English
6K: Material Agreement and Press Release: Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants,Extension of Second Nasdaq Compliance Period to Comply with Bid Price Rule
Regulatory Filings
2020-04-20 English
Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants
Share Issue/Capital Change
2020-04-20 English
Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants
Capital/Financing Update
2020-04-20 English
Amendment No. 1 to annual report on Form 20-F for the fiscal year ended 31.12.19, filed on 23.3.20
Annual Report FY 2019
2020-03-31 English
Amendment No. 1 to annual report on Form 20-F for the fiscal year ended 31.12.19, filed on 23.3.20
Regulatory Filings FY 2019
2020-03-31 English
Schedule 13G filing with the SEC by Armistice Capital, LLC
Major Shareholding Notification
2020-03-25 English
Schedule 13G filing with the SEC by Armistice Capital, LLC
Major Shareholding Notification
2020-03-25 English
Annual report for 2019 on form 20F
Annual Report FY 2019
2020-03-24 English
Annual report for 2019 on form 20F
Report Publication Announcement
2020-03-24 English
Schedule 13G filing with the SEC by CVI Investments, Inc.
Major Shareholding Notification
2020-03-21 English
Schedule 13G filing with the SEC by CVI Investments, Inc.
Major Shareholding Notification
2020-03-21 English
6k:Kitov Closes $6.0 Million Public Offering
Regulatory Filings
2020-03-17 English
6k:Kitov Closes $6.0 Million Public Offering
Report Publication Announcement
2020-03-17 English
PROSPECTUS Filed pursuant to Rule 424(b)(4) Registration No. 333-235729
Regulatory Filings
2020-03-16 English
PROSPECTUS Filed pursuant to Rule 424(b)(4) Registration No. 333-235729
Capital/Financing Update
2020-03-16 English
Press Release: Kitov Pharma Provides Update on Planned U.S. Launch of ConsensiTM and Provides Three-Year Revenue Forecast
Earnings Release Q1 2020
2020-03-12 English
Press Release: Kitov Pharma Provides Update on Planned U.S. Launch of ConsensiTM and Provides Three-Year Revenue Forecast
Regulatory Filings
2020-03-12 English
Kitov Announces Pricing of $6.0 Million Public Offering
Capital/Financing Update
2020-03-12 English
Kitov Announces Pricing of $6.0 Million Public Offering
Capital/Financing Update
2020-03-12 English
Amendment No. 2 to Form F-1
Regulatory Filings
2020-03-11 English
Amendment No. 2 to Form F-1
Report Publication Announcement
2020-03-11 English
Form F-1/A Registration Statement Under the Securities Act of 1933 Kitov Pharma Ltd.
Capital/Financing Update
2020-03-10 English
Form F-1/A Registration Statement Under the Securities Act of 1933 Kitov Pharma Ltd.
Report Publication Announcement
2020-03-10 English
Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers
Regulatory Filings
2020-02-24 English
Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers
Regulatory Filings
2020-02-24 English
Schedule 13G filing with the SEC by Pontifax (Israel) II L.P
Major Shareholding Notification
2020-02-16 English
Schedule 13G filing with the SEC by Pontifax (Israel) II L.P
Regulatory Filings
2020-02-16 English
Provides Corporate Update and Reports Full-Year 2019 Financial
Earnings Release FY 2019
2020-02-11 English
Provides Corporate Update and Reports Full-Year 2019 Financial
Regulatory Filings
2020-02-11 English
Corporate Update and Reports Full-Year 2019 Financial Results
Earnings Release FY 2019
2020-02-11 English
Corporate Update and Reports Full-Year 2019 Financial Results
Report Publication Announcement
2020-02-11 English
Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24
Regulatory Filings
2020-02-03 English
Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24
Regulatory Filings
2020-02-03 English
Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors
Regulatory Filings
2020-01-27 English
Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors
Regulatory Filings
2020-01-27 English
Press Release: Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors
Regulatory Filings
2020-01-25 English
Press Release: Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors
Regulatory Filings
2020-01-25 English
FORM D-Notice of Exempt Offering of Securities
Capital/Financing Update
2020-01-21 English
FORM D-Notice of Exempt Offering of Securities
Capital/Financing Update
2020-01-21 English
Schedule 13G/A filing with the SEC by EMPERY ASSET MANAGEMENT, LP / EMPERY AM GP, LLC / Ryan M. Lane concerning their holdings in the Company
Major Shareholding Notification
2020-01-18 English
Schedule 13G/A filing with the SEC by EMPERY ASSET MANAGEMENT, LP / EMPERY AM GP, LLC / Ryan M. Lane concerning their holdings in the Company
Report Publication Announcement
2020-01-18 English
Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer
Regulatory Filings
2020-01-09 English
Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer
Regulatory Filings
2020-01-09 English
Press Release: Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer
Board/Management Information
2020-01-09 English
Press Release: Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer
Board/Management Information
2020-01-09 English
Kitov Pharma Announces Closing of FameWave Acquisition
Capital/Financing Update
2020-01-08 English
Kitov Pharma Announces Closing of FameWave Acquisition
Report Publication Announcement
2020-01-08 English
Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule and Announces Closing of FameWave Acquisition
Regulatory Filings
2020-01-08 English
Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule and Announces Closing of FameWave Acquisition
Regulatory Filings
2020-01-08 English
Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule
Regulatory Filings
2020-01-08 English
Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule
Report Publication Announcement
2020-01-08 English
Press Release: Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule
Regulatory Filings
2020-01-08 English
Press Release: Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule
Report Publication Announcement
2020-01-08 English
Schedule 13G/A
Major Shareholding Notification
2020-01-03 English
Schedule 13G/A
Major Shareholding Notification
2020-01-03 English